Good clinical practice recommendations for the use of PET/CT in oncology-Reference-Cited by-同舟云学术

Good clinical practice recommendations for the use of PET/CT in oncology

Published:2019-10-21 Issue:1 Volume:47 Page:28-50
ISSN:1619-7070
Container-title:European Journal of Nuclear Medicine and Molecular Imaging
language:en
Short-container-title:Eur J Nucl Med Mol Imaging

Author:

Salaün Pierre-Yves^ORCID,Abgral Ronan,Malard Olivier,Querellou-Lefranc Solène,Quere Gilles,Wartski Myriam,Coriat Romain,Hindie Elif,Taieb David,Tabarin Antoine,Girard Antoine,Grellier Jean-François,Brenot-Rossi Isabelle,Groheux David,Rousseau Caroline,Deandreis Désirée,Alberini Jean-Louis,Bodet-Milin Caroline,Itti Emmanuel,Casasnovas Olivier,Kraeber-Bodere Françoise,Moreau Philippe,Philip Arnaud,Balleyguier Corinne,Luciani Alain,Cachin Florent

Publisher

Springer Science and Business Media LLC

Subject

Radiology, Nuclear Medicine and imaging,General Medicine,Radiology, Nuclear Medicine and imaging,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00259-019-04553-8.pdf

Reference27 articles.

1. Maurer T, Gschwend JE, Rauscher I, Souvatzoglou M, Haller B, Weirich G, et al. Diagnostic efficacy of (68)Gallium-PSMA positron emission tomography compared to conventional imaging for lymph node staging of 130 consecutive patients with intermediate to high risk prostate cancer. J Urol. 2016;195(5):1436–43.

2. von Eyben FE, Picchio M, von Eyben R, Rhee H, Bauman G. (68)Ga-labeled prostate-specific membrane antigen ligand positron emission tomography/computed tomography for prostate cancer: a systematic review and meta-analysis. Eur Urol Focus. 2018;4(5):686–93.

3. Bauman G, Martin P, Thiessen JD, Taylor R, Moussa M, Gaed M, et al. [(18)F]-DCFPyL positron emission tomography/magnetic resonance imaging for localization of dominant intraprostatic foci: first experience. Eur Urol Focus. 2018;4(5):702–6.

4. Giesel FL, Hadaschik B, Cardinale J, Radtke J, Vinsensia M, Lehnert W, et al. F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur J Nucl Med Mol Imaging. 2017;44(4):678–88.

5. Udovicich C, Perera M, Hofman MS, Siva S, Del Rio A, Murphy DG, et al. (68)Ga-prostate-specific membrane antigen-positron emission tomography/computed tomography in advanced prostate cancer: current state and future trends. Prostate Int. 2017;5(4):125–9.

Cited by 93 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role of [18F]FDG PET/CT in patients with no special type breast cancer: Literature review and comparison between guidelines;The Breast;2024-09

2. Diagnostic Performance of¹⁸F-FDG PET/CT According to Delay After Treatment to Detect Subclinical Recurrence of Head and Neck Squamous Cell Carcinoma;Journal of Nuclear Medicine;2024-07-11

3. Influence of Covariates on 18F-FDG PET/CT Diagnostic Accuracy for Liver Metastasis;Diagnostics;2024-07-09

4. Review on radiomic analysis in 18F-fluorodeoxyglucose positron emission tomography for prediction of melanoma outcomes;Cancer Imaging;2024-07-05

5. The emerging role of PET/CT scanning in the treatment planning of ovarian cancer: A mini-review;Imaging;2024-06-26